肺腺癌microRNA的表达与预后的关系及其与厄洛替尼药效的相关性研究

发布时间：2018-01-02 20:06

本文关键词：肺腺癌microRNA的表达与预后的关系及其与厄洛替尼药效的相关性研究　出处：《青岛大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的:截至目前,micro RNA致癌或抑癌作用机制尚未被研究透彻。本研究检测了肺腺癌根治术患者组织学标本micro RNA的表达谱,并探讨了特定micro RNA表达与预后的关系及其与厄洛替尼药效的相关性。方法:实验选取了226例病理分期为IIB及IIIA期肺腺癌根治术病人,分为实验组、对照组两个独立的回顾性研究组。实验组包括119例患者(80例EGFR突变,39例未突变),研究针对实验组病人肺腺癌病理组织及相邻正常肺实质,运用全基因组micro RNA分析确定了异常表达的micro RNA(micro RNA-21、145),并通过q RT-PCR分析其与预后关系。然后,运用q RT-PCR在由107例EGFR突变的肺腺癌病人组成验证组进一步验证异常表达micro RNA与预后的关系,并应用Cox比例风险回归分析其与厄洛替尼疗效间的关系。结果:实验中,病理标本micro RNA-21低表达肺腺癌病人总生存期明显延长(实验组P=0.0008;验证组P=0.0131),疾病进展未见缓慢(实验组P=0.6929,验证组P=0.3347)。此外,病理标本micro RNA-145高表达患者总生存期(实验组P=0.0198,验证组P=0.0269)、无进展生存期(实验组P=0.0198,验证组P=0.0269)明显长于低表达患者。值得一提的是micro RNA-21(77.3%vs 41.7%,P0.01)与micro RNA-145(71.4%vs 42.6%,P0.01)的表达对厄洛替尼的疗效影响巨大。病人EGFR突变情况与micro RNA表达也有着显著差异。结论:Micro RNA-21低表达的肺腺癌病人通常具有更长的的总生存期,但是对厄洛替尼疗效不甚显著。Micro RNA-145的高表达预示着更长的总生存期、无进展生存期,服用厄洛替尼也有更显著的疗效。
[Abstract]:Objective: up to now, the mechanism of carcinogenesis or tumor suppressor effect of micro RNA has not been thoroughly studied. In this study, the expression profile of micro RNA in histological specimens of patients with lung adenocarcinoma undergoing radical resection was detected. The relationship between the expression of specific micro RNA and prognosis and the efficacy of erlotinib was discussed. Methods:. Two hundred and twenty-two hundred and twenty-six patients with IIB and IIIA stages underwent radical resection of lung adenocarcinoma. Divided into experimental group, control group, two independent retrospective study group, the experimental group including 119 patients with 80 cases of EGFR mutation in 39 cases without mutation). The aim of this study was to study the pathological tissue and adjacent normal lung parenchyma of patients with lung adenocarcinoma in experimental group. The abnormal expression of micro RNA(micro RNA-21p145 was determined by genomic micro RNA analysis. The relationship between Q RT-PCR and prognosis was analyzed. Q RT-PCR was used to further verify the relationship between abnormal expression of micro RNA and prognosis in 107 lung adenocarcinoma patients with EGFR mutation. Cox proportional risk regression analysis was used to analyze the relationship between the efficacy of erlotinib and the efficacy of erlotini.Results: in the experiment. The overall survival time of lung adenocarcinoma patients with low expression of micro RNA-21 was significantly prolonged (P0. 0008). In the test group, the disease progress was not slow (P0. 6929 in the experimental group and P0. 3347 in the validation group). The total survival time of the patients with high expression of micro RNA-145 was 0.0198 in the experimental group and 0.0269 in the validation group. Progression-free survival time (P0. 0198). Micro RNA-21(77.3%vs 41.7% was significantly longer in the validation group than in the low expression group. P0.01) and micro RNA-145(71.4%vs 42.6%. P0.01). There was significant difference between EGFR mutation and micro RNA expression in patients. Conclusion\\\%\%\%\%\%\%\%\; Lung adenocarcinoma patients with low expression of RNA-21 usually have longer total survival. However, the high expression of erlotinib was not significant. The high expression of Micro RNA-145 predicted a longer overall survival and progression free survival, as well as a more significant effect on erlotinib.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R734.2

【相似文献】